November 2, 2006 -- Exelixis put a hold on new patients in a trial of an anti-cancer drug because of a high rate of cardiovascular side effects; Ariad said its cancer drug produced very strong data in a Phase II trial; CuraGen and TopoTarget will out-license a preclinical psoriasis drug candidate; Enzon Pharma got clearance to begin human testing of an anti-infective drug in liver transplant patients; Bentley Pharma began a Phase II trial of its Intranasal Insulin Spray drug; Tercica said a New Drug Application was submitted for its acromegaly therapy; and Xoma will collaborate with Takeda to discover and develop therapeutic monoclonal antibodies. The Centient Biotech 200™ fell 15 points to 3940, a .37% loss. More details...
